Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma
Authors:
Open Access
- 1 June 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (24) , e11130
Abstract
Glypican-3 (GPC3) has been widely recognized in the progression of liver tumors for several years. The relationship between overexpression of GPC3 and the poorer prognosis of patients with hepatocellular carcinoma (HCC) was performed by 2 meta-analyses. However, there were also some latest literatures that indicated different conclusions distinctly. It is necessary for us to carry out a meta-analysis by adding the latest data from current studies to explore the correlation between GPC3 and prognostic value in HCC. We conducted a meta-analysis including a total of 14 studies to assess the potential prognostic significance of GPC3 expression for overall survival (OS) and disease-free survival (DFS). The expression of GPC3 was assessed by immunohistochemistry. Fourteen studies with 2364 patients were incorporated in the meta-analysis. The combined hazard ratios (HRs) revealed that the overexpression of GPC3 could forecast a poor OS [n = 2233 in 12 studies, HR = 1.40, 95% confidence interval (95% CI): 1.07–1.85, Z = 2.42, P = .02] and DFS (n = 1308 in 10 studies, HR = 1.61, 95% CI: 1.13–2.30, Z = 2.63, P = .008) in HCC patients. Subgroup treated by hepatectomy indicated that the pooled HR of OS was 1.43 (95% CI: 1.01–2.01, P = .04) and the combined HR of DFS was 1.59 (95% CI: 1.09–2.31, P = .02). The pooled odds ratios (ORs) showed that high GPC3 expression was also extensively associated with worse tumor differentiation, later tumor stage, presence of vascular invasion, and hepatitis B virus (HBV) infection. Subgroup analyses for GPC3 on HCC OS based on the studies categorized by regions, follow-up period, and sample size were also conducted. The meta-analysis indicated that overexpression of GPC3 was significantly associated with poor prognosis in patients with HCC.Keywords
This publication has 42 references indexed in Scilit:
- Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resectionSurgery, 2013
- Clinicopathological and Prognostic Significance of Survivin Over-Expression in Patients with Esophageal Squamous Cell Carcinoma: A Meta-AnalysisPLOS ONE, 2012
- Glypican-3 expression and its relationship with recurrence of HCC after liver transplantationWorld Journal of Gastroenterology, 2012
- Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell lineInternational Journal of Molecular Medicine, 2011
- Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomasJournal of Clinical Pathology, 2011
- Prognostic significance of circumferential cell surface immunoreactivity of glypican‐3 in hepatocellular carcinomaLiver International, 2010
- Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinomaCancer Science, 2009
- GlypicansGenome Biology, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- A decade?s studies on metastasis of hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2003